Skip to main content
    V

    Verrica Pharmaceuticals Inc (VRCA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.20
    -0.36 (-10.11%)

    Market Cap: $61.16M

    Last updated: Nov 17, 2026 at 10:43 AM ET

    Verrica Pharmaceuticals Inc (VRCA) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Verrica Pharmaceuticals (VRCA) to earn -$1.88 per share in the fiscal year ending Dec 31, 2026, on revenue of $24.39M. Of 7 analysts, 6 rate the stock Buy or Strong Buy, 1 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.14, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 86% of the ratings.

    RatingAnalystsShare
    Strong Buy00.0%
    Buy685.7%
    Hold114.3%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    7

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss and revenue estimates rise 60.8%.

    Fiscal year ending Dec 31, 2026
    -$1.88
    EPS consensus, revenue $24.39M
    Fiscal year ending Dec 31, 2027
    -$1.24
    EPS consensus, revenue $39.22M
    Next report
    Mar 8, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.88-$2.03 to -$1.704$24.39M$22.60M to $26.60M7
    Dec 31, 2027-$1.24-$1.50 to -$0.854$39.22M$31.20M to $49.70M7

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.49-$0.67 to -$0.339$7.25M$6.17M to $8.26M9

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 2 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202610
    Fiscal year ending Dec 31, 202710

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.73.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.88-$1.97-$1.97-$2.01-$1.73N/A
    Fiscal year ending Dec 31, 2027-$1.24-$1.48-$1.48-$1.47-$1.24N/A

    Frequently Asked Questions About VRCA

    What is the VRCA stock forecast?

    Consensus analyst estimates put Verrica Pharmaceuticals's EPS at -$1.88 for the fiscal year ending Dec 31, 2026, on revenue of $24.39M. The consensus rating from 7 analysts is Buy.

    How do analysts rate VRCA stock?

    Of 7 analysts covering Verrica Pharmaceuticals, 0 rate it Strong Buy, 6 Buy, 1 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from VRCA next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.88, with estimates from -$2.03 to -$1.70 from 4 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.24, with estimates from -$1.50 to -$0.85 from 4 analysts.

    What revenue do analysts expect from Verrica Pharmaceuticals next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $24.39M, with estimates from $22.60M to $26.60M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $39.22M, with estimates from $31.20M to $49.70M.

    How many analysts cover VRCA?

    7 analysts rate Verrica Pharmaceuticals stock, and 4 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.